Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.95 |
| ▸ | HPGD | P15428 | 6/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.95 |
| ▸ | CA12 | O43570 | 2/20 | 0.95 |
| ▸ | CA1 | P00915 | 2/20 | 0.95 |
| ▸ | CA2 | P00918 | 2/20 | 0.95 |
| ▸ | CA7 | P43166 | 2/20 | 0.95 |
| ▸ | CA9 | Q16790 | 2/20 | 0.95 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.95 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.95 |
| ▸ | CA4 | P22748 | 1/20 | 0.95 |
| ▸ | CA6 | P23280 | 1/20 | 0.95 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.95 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | G6PD | P11413 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL29362663 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL8433746 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29606432 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1967 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1509155 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL17156443 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29360246 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL971594 | 0.95 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL162965 | 0.95 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL15365856 | 0.95 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114471457-B | Adsorption material and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-114471457-A | Adsorbing material and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-102086280-A | Preparation method of polypropylene nano composite material | CHINA PETROLEUM & CHEMICAL | 2011-06-08 | — | — | CN | claimed |
| US-6676973-B1 | SUCH AS CADMIUM CHLORIDE AS TUMOR TOXIC AGENT | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-01-13 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-12491493-B1 | Amine appended bimetallic metal-organic framework (MOF-74) for carbon dioxide capture and method of preparation thereof | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-12-09 | — | — | US | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-114471457-B | Adsorption material and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023118074-A1 | COMPRESSIBLE AND FREE FLOWING CO-PROCESSED MESOPOROUS SILICA | UNIVERZA V LJUBLJANI (SI) | 2023-06-29 | — | — | WO | disclosed |
| WO-1999015210-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5463086-A | Dissolving a crude lactide in a weak and strong solvent mixture then recrystallizing | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1995-10-31 | — | — | US | disclosed |
| US-5236981-A | STABILIZED HALOGENATED POLYMER COMPOSITIONS CONTAINING A LEAD OR ORGANOTIN COMPOUND | RHONE-POULENC CHIMIE (FR) | 1993-08-17 | — | — | US | disclosed |
| US-5234981-A | HALOGENATED POLYMER COMPOSITIONS STABILIZED WITH THE AID OF AN INORGANIC ADDITIVE | RHONE-POULENC CHIMIE (FR) | 1993-08-10 | — | — | US | disclosed |
| US-4851566-A | CONDENSING ALKYL MALONATE WITH ORTHOESTER IN PRESENCE OF CARBOXYLIC ACID AND CADMIUM OR MAGNESIUM COMPOUND CATALYST | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1989-07-25 | — | — | US | disclosed |
| US-4738796-A | HEAT STABILIZATION USING MIXTURE OF 8-HYDROXYQUINOLINE AND ORGANIC PHOSPHATES | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1988-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | ALDH1A1 2174/4885KDM4E 2452/4885HPGD 101/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | ALDH1A1 3977/4885KDM4E 3249/4885HPGD 1241/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | ALDH1A1 2230/4885KDM4E 2466/4885HPGD 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.